scispace - formally typeset
Ł

Łukasz Kruszyna

Researcher at Poznan University of Medical Sciences

Publications -  28
Citations -  390

Łukasz Kruszyna is an academic researcher from Poznan University of Medical Sciences. The author has contributed to research in topics: Genotype & Population. The author has an hindex of 11, co-authored 26 publications receiving 290 citations.

Papers
More filters
Journal ArticleDOI

Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.

TL;DR: The Cmax of the active H4 isomer and platelet aggregation measured by the Multiplate analyser may serve as markers of the patient response to clopidogrel therapy.
Journal ArticleDOI

Polymorphic variants of folate metabolism genes and the risk of laryngeal cancer

TL;DR: The significance of the role of the methyl cycle in etiopathogenesis of laryngeal cancer is confirmed and polymorphic variants of genes encoding enzymes of folate and methionine metabolism are examined using PCR-RFLPs.
Journal ArticleDOI

Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite.

TL;DR: It was found that the only significant covariate was the presence of CYP2C19*2 allele, which had an impact on lower conversion of clopidogrel to H4, and predicted area under the time-concentration curve values was lower in carriers of this allele.
Journal Article

Mutations within protein kinase R-binding domain of NS5A protein of hepatitis C virus (HCV) and specificity of HCV antibodies in pretreatment sera of HCV-chronically infected patients and their effect on the result of treatment.

TL;DR: It is indicated that mutations in the PKR-binding domain of HCV genotype 1b do not correlate with outcome of PEG-IFN-alpha/RBV therapy, however, the presence of E2-specific antibodies in the pretreatment sera ofHCV-chronically infected individuals could serve as a prognostic marker predicting the result of treatment, before its initiation.